MedTrace Logo

CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study

NCT04384770 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 179

Last updated 2026-05-11

No results posted yet for this study

Summary

This phase III trial studies compares CT-guided stereotactic body radiation therapy and MRI-guided stereotactic body radiation therapy (SBRT) in treating prostate cancer. Image-guided SBRT is a standard treatment for prostate cancer, which combines imaging of the cancer within the body with the delivery of therapeutic radiation doses produced on a linear accelerator machine. Imaging modalities for image-guided SBRT can be either computed tomography imaging (CT), magnetic resonance imaging (MRI), or a combination of the two. This research is being done to help determine whether there are benefits to MRI-guidance over CT-guidance in patients who are receiving the same radiation dose by SBRT to treat prostate cancer.

Conditions

  • Prostate Adenocarcinoma

Interventions

RADIATION

CT-guided Stereotactic Body Radiation Therapy

Undergo CT-guided SBRT

RADIATION

MRI-guided Stereotactic Body Radiation Therapy

Undergo MRI-guided SBRT

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Amar Kishan · UCLA / Jonsson Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-12
Primary Completion
2027-04-01
Completion
2028-04-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04384770 on ClinicalTrials.gov